Cover
Cover | 12 Months Ended |
Dec. 31, 2021 | |
Cover [Abstract] | |
Document Type | S-1/A |
Amendment Flag | true |
Amendment Description | AMENDMENT NO. 1 |
Entity Registrant Name | Curative Biotechnology Inc |
Entity Central Index Key | 0001400271 |
Entity Primary SIC Number | 2836 |
Entity Tax Identification Number | 26-1412177 |
Entity Incorporation, State or Country Code | FL |
Entity Address, Address Line One | 1825 NW Corporate Blvd |
Entity Address, Address Line Two | Suite 110 |
Entity Address, City or Town | Boca Raton |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33431 |
City Area Code | (561) |
Local Phone Number | 907-8990 |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
Document Creation Date | Apr. 25, 2022 |
Balance Sheets
Balance Sheets - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
CURRENT ASSETS | ||
Cash | $ 670,263 | $ 160,607 |
Subscription receivable | 25,000 | |
Prepaid expenses | 58,642 | 1,900,859 |
Funds receivable on notes payable | 70,000 | |
Total current assets | 753,905 | 2,131,466 |
FIXED ASSETS | ||
Property and equipment | 6,834 | 81,515 |
Accumulated depreciation | (114) | (79,177) |
Total fixed assets | 6,720 | 2,338 |
OTHER ASSETS | ||
Deferred offering costs | 92,975 | |
Intangible assets, net | 1,558,550 | 140,300 |
Total other assets | 1,651,525 | 140,300 |
Total Assets | 2,412,150 | 2,274,104 |
CURRENT LIABILITIES | ||
Accounts payable and accrued liabilities | 726,904 | 97,830 |
Convertible note payable | 128,700 | |
Liability to issue common shares | 3,431 | 7,400 |
Short term note payable - related parties, net of discounts | 25,415 | |
Third party short term loans, net of discounts | 405,646 | |
Total current liabilities | 730,335 | 664,991 |
Total Liabilities | 730,335 | 664,991 |
Commitments and Contingencies | ||
DEFICIENCY IN STOCKHOLDERS’ EQUITY | ||
Preferred stock, $0.0001 par value, authorized 200,000,000 shares, Series B 81,000 and 293,000 shares issued and outstanding | 8 | 29 |
Common stock, $0.0001 par value, authorized 1,100,000,000 shares; 570,651,636 and 333,000,327 shares issued and outstanding | 57,065 | 33,300 |
Additional paid-in capital | 10,498,221 | 3,544,658 |
Accumulated deficit | (26,917,036) | (8,099,627) |
Total deficiency in stockholders’ equity | (16,361,742) | (4,521,640) |
Total Liabilities and Deficiency in Stockholders’ Equity | 2,412,150 | 2,274,104 |
Series A Preferred Stock [Member] | ||
CURRENT LIABILITIES | ||
Temporary stock, value | 1,564,251 | |
Series C Preferred Stock [Member] | ||
CURRENT LIABILITIES | ||
Temporary stock, value | $ 18,043,557 | $ 4,566,502 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 1,100,000,000 | 1,100,000,000 |
Common stock, shares issued | 570,651,636 | 333,000,327 |
Common stock, shares outstanding | 570,651,636 | 333,000,327 |
Series A Preferred Stock [Member] | ||
Temporary equity, shares issued | 0 | 134,109,750 |
Temporary equity, shares outstanding | 0 | 134,109,750 |
Series C Preferred Stock [Member] | ||
Temporary equity, shares issued | 30,000,000 | 30,000,000 |
Temporary equity, shares outstanding | 30,000,000 | 30,000,000 |
Series B Preferred Stock [Member] | ||
Preferred stock, shares issued | 81,000 | 293,000 |
Preferred stock, shares outstanding | 81,000 | 293,000 |
Statements of Operations
Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | ||
REVENUES | ||
COST OF REVENUES | ||
GROSS MARGIN | ||
OPERATING EXPENSES: | ||
General and administrative expenses | 4,211,355 | 4,598,302 |
Research and development expenses | 779,275 | |
Impairment of long-lived assets | 16,958 | 32,136 |
Depreciation and amortization | 6,744 | 5,301 |
Total expenses | 5,014,332 | 4,635,739 |
Loss from operations | (5,014,332) | (4,635,739) |
Other expense: | ||
Interest expense | 176,672 | 34,516 |
Loss on debt extinguishment | 149,350 | |
Total other expense | 326,022 | 34,516 |
Net loss | (5,340,354) | (4,670,255) |
Series C deemed dividend | (13,477,055) | (4,440) |
Net loss to common shareholders | $ (18,817,409) | $ (4,674,695) |
(Loss) income per basic weighted average common share | $ (0.04) | $ (0.01) |
Number of weighted average basic and diluted common shares outstanding | 500,981,957 | 326,678,469 |
Statement of Deficiency in Stoc
Statement of Deficiency in Stockholders' Equity - USD ($) | Common Stock [Member] | Preferred Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total | |||
Balance at Dec. 31, 2019 | $ 32,280 | $ 29 | $ 3,304,188 | $ (3,424,932) | $ (88,435) | |||
Balance, shares at Dec. 31, 2019 | 322,800,327 | 34,402,750 | ||||||
Common shares issued for services | $ 170 | 36,630 | 36,800 | |||||
Common shares issued for services, shares | 1,700,000 | |||||||
Common shares issued for intangible assets | $ 850 | 105,150 | 106,000 | |||||
Common shares issued for intangible assets, shares | 8,500,000 | |||||||
Warrants issued in connection with debt | 54,555 | 54,555 | ||||||
Warrants issued for services | 44,135 | 44,135 | ||||||
Preferred stock Series A issued for services | [1] | [1] | [1] | |||||
Preferred stock Series A issued for services, shares | 100,000,000 | |||||||
Preferred stock Series C issued for services | [1] | [1] | [1] | |||||
Preferred stock Series C issued for services, shares | 30,000,000 | |||||||
Series C deemed dividend | [1] | (4,440) | (4,440) | |||||
Net loss | (4,670,255) | (4,670,255) | ||||||
Balance at Dec. 31, 2020 | $ 33,300 | $ 29 | 3,544,658 | (8,099,627) | (4,521,640) | |||
Balance, shares at Dec. 31, 2020 | 333,000,327 | 164,402,750 | ||||||
Common shares issued for services | $ 872 | 539,264 | 540,136 | |||||
Common shares issued for services, shares | 8,715,000 | |||||||
Common shares issued for intangible assets | $ 1,250 | 1,423,750 | 1,425,000 | |||||
Common shares issued for intangible assets, shares | 12,500,000 | |||||||
Warrants issued in connection with debt | 9,533 | 9,533 | ||||||
Warrants issued for services | 485,487 | 485,487 | ||||||
Common stock issued for conversion of Preferred stock Series A | $ 13,584 | [1] | 1,550,667 | 1,564,251 | ||||
Common stock issued for conversion of Preferred stock Series A, shares | 135,836,702 | (134,109,750) | ||||||
Common stock issued for conversion of Preferred stock Series B | $ 2,826 | $ (21) | (2,805) | 0 | ||||
Common stock issued for conversion of Preferred stock Series B, shares | 28,266,666 | (212,000) | ||||||
Shares issued for cash | $ 2,752 | 1,570,248 | 1,573,000 | |||||
Shares issued for cash, shares | 27,520,442 | |||||||
Shares issued to convert debt | $ 1,094 | 655,156 | 656,250 | |||||
Shares issued to convert debt, shares | 10,937,499 | |||||||
Warrant exercises for cash | $ 1,050 | 523,950 | 525,000 | |||||
Warrant exercises for cash, shares | 10,500,000 | |||||||
Shares issued to settle payables | $ 37 | 11,213 | 11,250 | |||||
Shares issued to settle payables, shares | 375,000 | |||||||
Shares issued to settle debt | $ 200 | 179,800 | 180,000 | |||||
Shares issued to settle debt, shares | 2,000,000 | |||||||
Shares issued to settle liability to issue shares | $ 100 | 7,300 | 7,400 | |||||
Shares issued to settle liability to issue shares, shares | 1,000,000 | |||||||
Series C deemed dividend | [1] | (13,477,055) | (13,477,055) | |||||
Net loss | (5,340,354) | (5,340,354) | ||||||
Balance at Dec. 31, 2021 | $ 57,065 | $ 8 | $ 10,498,221 | $ (26,917,036) | $ (16,361,742) | |||
Balance, shares at Dec. 31, 2021 | 570,651,636 | 30,081,000 | ||||||
[1] | Series A and Series C Preferred Stock amounts reflected in mezzanine equity |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (5,340,354) | $ (4,670,255) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 6,744 | 5,301 |
Share based compensation | 2,889,567 | 4,302,978 |
Amortization of warrant discount | 2,545 | 11,495 |
Amortization of Original Issue Discount | 122,129 | 19,121 |
Loss on debt extinguishment | 149,350 | |
Impairment of long lived assets | 16,958 | 32,136 |
Changes in operating assets and liabilities | ||
(Increase) in stock subscription receivable | (25,000) | |
(Increase) in prepaid expenses | (18,294) | |
Increase in accounts payable and accrued expenses | 592,320 | 109,131 |
Net cash used in operating activities | (1,604,035) | (190,093) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchase of fixed assets | (6,834) | |
Purchase of intangible assets | (14,500) | (34,300) |
Net cash used in investing activities | (21,334) | (34,300) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Cash received for issuance of common stock | 1,573,000 | |
Cash received for exercise of warrants | 525,000 | |
Cash received for amounts receivable on notes payable | 70,000 | |
Cash paid for deferred offering costs | (92,975) | |
Advances from related party | 48,083 | |
Payments on related party advances | (48,083) | |
Payments on related party notes payable | (50,000) | |
Cash received from related party notes payable | 20,000 | |
Cash received from third party notes payable | 110,000 | 365,000 |
Net cash provided by financing activities | 2,135,025 | 385,000 |
Net increase in cash | 509,656 | 160,607 |
CASH, beginning of year | 160,607 | |
CASH, end of year | 670,263 | 160,607 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
Interest paid in cash | 10,000 | |
Income taxes paid in cash | ||
Non-Cash Financing Activities: | ||
Common shares issued for intangible assets | 1,425,000 | 106,000 |
Common shares issued upon conversion of debt | 656,250 | |
Common shares issued upon conversion of preferred stock | 1,564,251 | |
Warrants issued as debt discount | 9,533 | 54,555 |
Series C preferred stock deemed dividend | 13,477,055 | 4,440 |
Common shares issued to settle liabilities | $ 198,650 |
NATURE OF OPERATIONS
NATURE OF OPERATIONS | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NATURE OF OPERATIONS | NOTE 1 - NATURE OF OPERATIONS Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined “Orphan Diseases” with patient populations under 200,000 in the United States. The company leverages management’s experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the company’s business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market. |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a) Basis of Presentation b) Use of Estimates (c) Cash and equivalents (d) Prepaid expenses (e) Property and equipment (f) Intangible Assets Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. (g) Impairment of Long-Lived Assets Curative Biotechnology, Inc Notes to Financial Statements NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) Related Party Transactions (j) Revenue Recognition (k) Stock based compensation Curative Biotechnology, Inc Notes to Financial Statements NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (l) Income Taxes (m) Net income (loss) per share no . (n) Recent Accounting Pronouncements |
LIQUIDITY AND GOING CONCERN CON
LIQUIDITY AND GOING CONCERN CONSIDERATIONS | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
LIQUIDITY AND GOING CONCERN CONSIDERATIONS | NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern, as reflected by the net loss of approximately $ 5.3 26.9 |
INTANGIBLE ASSETS
INTANGIBLE ASSETS | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS | NOTE 4 - INTANGIBLE ASSETS During the 4 th (a) MABT Covid-19 license 12,500,000 1,425,000 During the 4 th (b) Website 22,500 3 6,250 In March 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of $ 15,000 1,500,000 Curative Biotechnology, Inc Notes to Financial Statements NOTE 4 - INTANGIBLE ASSETS, continued ( c) Patent rights option 1,800 The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $ 50,000 1,000 (d) IMT504 Patent license 6.5 The total cost for this license is 20 1 7 91,000 2 6.5 3 6.5 (e) National Institute of Health (NIH) Patent license #1 This license calls for the payment of a non-creditable non-refundable license issue royalty of $ 10,000 (f) National Institute of Health (NIH) Patent license #2 This license requires two separate royalty streams of payments: First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of $ 8,500 Curative Biotechnology, Inc Notes to Financial Statements NOTE 4 - INTANGIBLE ASSETS, continued (f) National Institute of Health (NIH) Patent license #2 Second is an ongoing royalty schedule: an initial royalty of $ 5,000 The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $ 45,000 The patent rights and patent licenses are under development, therefore amortization of the costs has not commenced, as these patent rights and licenses have not been placed in service. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 5 - RELATED PARTY TRANSACTIONS From time to time the Company may enter into non-arms length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arms length transaction. During 2020, one officer advanced $ 48,083 During the second quarter of 2021, the remaining two notes from officers of the Company, totaling $ 40,000 10,000 |
NOTES PAYABLE
NOTES PAYABLE | 12 Months Ended |
Dec. 31, 2021 | |
Notes Payable | |
NOTES PAYABLE | NOTE 6 - NOTES PAYABLE During the first quarter 2021, 13 of the 15 total notes were converted into 10,937,499 In January 2021, the amounts receivable for notes payable were received. During the first quarter of 2021, the Company entered into two (2) notes payable with a face amount of $ 137,500 25 110,000 six months 25 The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee 1,100,000 9,533 9.24 During 2020, the Company issued thirteen (13) notes payable with a face amount of $ 568,750 , including 25 % OID, for a total amount of cash received of $ 455,000 . The notes are identical and carry a six month maturity. The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee . In connection with the notes, the Company issued warrants to purchase 4,550,000 shares of common stock of the Company, which were recorded as a discount in the amount of $ 54,555 , which is being amortized over the term of the notes. These notes are collateralized by Preferred C shares representing 9.24 % of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral. During the first quarter of 2021, 13 of the 15 note holders converted their notes into shares of common stock at the rate of $ 0.06 per share, for a total of 10,937,499 shares of common stock for a total of $ 656,250 convertible debt. Curative Biotechnology, Inc Notes to Financial Statements |
CONVERTIBLE NOTE PAYABLE
CONVERTIBLE NOTE PAYABLE | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
CONVERTIBLE NOTE PAYABLE | NOTE 7 - CONVERTIBLE NOTE PAYABLE In April 2013, the Company entered into a convertible note in the principal amount of $ 97,500 4 90 0.001 128,700 100,000 2,000,000 |
LIABILITY TO ISSUE COMMON STOCK
LIABILITY TO ISSUE COMMON STOCK | 12 Months Ended |
Dec. 31, 2021 | |
Liability To Issue Common Stock | |
LIABILITY TO ISSUE COMMON STOCK | NOTE 8 - LIABILITY TO ISSUE COMMON STOCK In March 2020, the Company entered into an agreement to issue 1,000,000 7,400 |
DEFICIENCY IN STOCKHOLDERS EQUI
DEFICIENCY IN STOCKHOLDERS EQUITY | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
DEFICIENCY IN STOCKHOLDERS EQUITY | NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY At December 31, 2021 and 2020, the Company has 1,100,000,000 0.0001 570,651,636 333,000,327 200,000,000 0.0001 The Company accounts for the Series A and Series C preferred stock in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY No. Shares Par No. Shares Par No. Shares Par No. Shares Par Series A Series B Series C Total No. Shares Par No. Shares Par No. Shares Par No. Shares Par January 1, 2020 34,109,750 $ 3,411 293,000 $ 29 - $ - 34,402,750 $ 3,440 Issuance of shares for services 100,000,000 10,000 - - 30,000,000 3,000 130,000,000 13,000 December 31, 2020 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Beginning Balance 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Conversion to common shares (134,109,750 ) (13,411 ) (212,000 ) (21 ) - - (134,321,750 ) (13,432 ) December 31, 2021 - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 Ending Balance - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 The preferred shares have the following respective rights and privileges: Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date 35 45 5,000,000 Series B Preferred are convertible in common shares of common stock at a conversion price of $ 0.0075 125 Series C Preferred are convertible into common stock aggregating 30 Curative Biotechnology, Inc Notes to Financial Statements NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the fourth quarter 2021, the Company issued 13,159,331 25,915,437 523,000 25,000 200,000 21,960 12,500,000 1,425,000 During the third quarter 2021, the Company issued 4,361,111 4,236,111 425,000 250,000 22,500 60,000 60,000 60,000 70,000 300,000 36,720 250,000 28,475 2,000,000 180,000 9,000 1,200,000 During the second quarter 2021, the Company issued 10,000,000 5,000,000 600,000 May 2026 0.11 1,000,000 During the second quarter 2021, the Company issued 250,000 60,000 60,000 60,000 70,000 840,000 210,000 210,000 210,000 210,000 840,000 During the first quarter 2021, the Company issued 125,000 5,575 0.0446 375,000 11,250 135,836,702 203,000 27,066,666 0.06 10,937,499 656,250 10,500,000 10,500,000 6,500,000 6,500,000 325,000 During the 4 th 1,700,000 36,800 0.0216 th 8,500,000 106,000 0.0125 During the 4 th 100,000,000 1,560,840 0.0156 th 30,000,000 4,562,062 0.152 50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which will be amortized over the remaining of the six month service period. During the 2nd quarter 2020, the Company issued 1,250,000 23,300 0.01864 Curative Biotechnology, Inc Notes to Financial Statements NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the 1st quarter 2020, the Company issued 1,500,000 15,000 0.01 A deemed dividend for the Series C preferred stock is calculated and recorded as shares of common stock are issued. This is calculated as the increase in common shares that the Series C would receive upon conversion, as a result of the change in the number of common shares issued and outstanding during the period multiplied by the closing price of the common stock at the end of the period. The deemed dividend was 13,477,055 4,440 |
WARRANTS
WARRANTS | 12 Months Ended |
Dec. 31, 2021 | |
Warrants | |
WARRANTS | NOTE 10 - WARRANTS During the fourth quarter 2021, the Company issued 403,225 403,225 December 2024 0.11 25,512,212 12,756,106 December 2024 0.09 0.15 During the third quarter 2021, the Company issued 4,236,111 4,361,111 July and August 2026 0.15 0.14 1,000,000 July 2024 0.124 34,382 During the second quarter 2021, the Company issued 5,000,000 10,000,000 May 2026 0.11 5,000,000 0.20 87,249 3,000,000 0.10 155,717 During the second quarter 2021, the Company issued 1,000,000 0.10 51,906 250,000 During the first quarter 2021, the Company issued 10,500,000 525,000 10,500,000 6,500,000 325,000 6,500,000 In the first quarter 2021, the Company issued 1,100,000 the Company in conjunction with the short term debt at the rate of 10 warrants for each $1 loaned. 0.05 9,533 In the first quarter 2021, the Company issued 5,000,000 0.05 40,600 The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years 0.04 0.10 60.51 31.56 0.05 0.2 0.09 0.83 Curative Biotechnology, Inc Notes to Financial Statements NOTE 10 - WARRANTS, continued During the 4 th 4,550,000 the Company in conjunction with the issuance of short term debt at the rate of 10 warrants for each $1 loaned 0.05 54,555 During the 4 th 6,750,000 0.05 44,135 The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life three years 0.03 109.96 30.22 0.05 0.08 0.11 |
OPTIONS
OPTIONS | 12 Months Ended |
Dec. 31, 2021 | |
Share-Based Payment Arrangement [Abstract] | |
OPTIONS | NOTE 11 - OPTIONS In the third quarter of 2021, the Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1 8,081,037 5 0.11 436,908 50 50% The method utilized to value the options was the Black-Scholes model with the following assumption ranges: Expected life - ten years 0.114 35.13 0.11 1.47 |
FINANCIAL INSTRUMENTS
FINANCIAL INSTRUMENTS | 12 Months Ended |
Dec. 31, 2021 | |
Investments, All Other Investments [Abstract] | |
FINANCIAL INSTRUMENTS | NOTE 12 - FINANCIAL INSTRUMENTS (a) Liquidity Risk (b) Interest Rate Risk |
GENERAL AND ADMINISTRATIVE EXPE
GENERAL AND ADMINISTRATIVE EXPENSES | 12 Months Ended |
Dec. 31, 2021 | |
General And Administrative Expenses | |
GENERAL AND ADMINISTRATIVE EXPENSES | NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE 2021 2020 Year ended December 31, 2021 2020 Salaries $ 1,016,881 $ 143,065 Share based compensation 2,889,567 4,302,978 Professional fees 225,384 117,860 Other 79,523 34,399 Total general and administrative expenses $ 4,211,355 $ 4,598,302 Curative Biotechnology, Inc Notes to Financial Statements |
IMPAIRMENT OF LONG LIVED ASSETS
IMPAIRMENT OF LONG LIVED ASSETS | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
IMPAIRMENT OF LONG LIVED ASSETS | NOTE 14 - IMPAIRMENT OF LONG LIVED ASSETS In the fourth quarter the Company determined that its fixed assets were obsolete and wrote off the undepreciated balance of $ 1,958 In March 2021, when the Company’s new website was placed in service, the remaining unamortized cost of the Company’s old website was written off, for a total of $ 15,000 During the 4 th 34,516 |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | NOTE 15 - INCOME TAXES The Company recognizes deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized. The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2021 2020 Current $ - $ - Deferred $ - $ - Total tax provisions $ - $ - The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE 2021 2020 U.S. Federal statutory income tax rate (21 )% (21 )% State income tax, net of federal benefit (4.5 )% (4.5 )% Valuation allowance 25.5 % 25.5 % Total 0.0 % 0.0 % The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Deferred tax assets: Net operating loss carry forwards $ 1,337,957 $ 831,988 Stock based compensation 1,600,548 958,197 Other - (10,061 ) Total 2,938,505 1,780,124 Deferred tax liabilities: - - Less: valuation allowance (2,938,505 ) (1,780,124 ) Net deferred tax assets $ - $ - Curative Biotechnology, Inc Notes to Financial Statements NOTE 15 - INCOME TAXES, continued The change in valuation allowance was ($ 1,158,381 1,021,331 100 The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2021 and 2020, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 16 - COMMITMENTS AND CONTINGENCIES (a) Other |
CONCENTRATIONS OF CREDIT RISK
CONCENTRATIONS OF CREDIT RISK | 12 Months Ended |
Dec. 31, 2021 | |
Risks and Uncertainties [Abstract] | |
CONCENTRATIONS OF CREDIT RISK | NOTE 17 - CONCENTRATIONS OF CREDIT RISK (a) Cash 416,178 no |
COVID-19 PANDEMIC AND VARIANTS
COVID-19 PANDEMIC AND VARIANTS | 12 Months Ended |
Dec. 31, 2021 | |
Unusual or Infrequent Items, or Both [Abstract] | |
COVID-19 PANDEMIC AND VARIANTS | NOTE 18 - COVID-19 PANDEMIC AND VARIANTS The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 19 - SUBSEQUENT EVENTS (a) Intangible Assets (b) Senior Secured Note 1,142,857 , with a stated 12.5 % original issue discount (OID). The Note carries a 12.5% . The Company received $ 874,286 in cash, net of the OID of $ 142,857 and legal and other fees in the amount of $ 125,714 . The Note was issued to Puritan Partners, LLC, an institutional investor. Beginning in September 2022, the Company is required to make monthly redemptions at the rate of 110 179,592 125% 1,428,571 The Note is convertible into common stock of the Company upon an event of default, as defined. The lender received five year warrants to purchase 22,857,143 0.0001 1.0 The Note is secured by all the tangible and intangible assets of the Company. NOTE 19 - SUBSEQUENT EVENTS, continued (c) Deficiency in Stockholders Equity 1,000,000 51,750 In January 2022, the $ 25,000 (d) Options 7,465,500 five year 0.05175 155,250 |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | a) Basis of Presentation |
Use of Estimates | b) Use of Estimates |
Cash and equivalents | (c) Cash and equivalents |
Prepaid expenses | (d) Prepaid expenses |
Property and equipment | (e) Property and equipment |
Intangible Assets | (f) Intangible Assets Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. |
Impairment of Long-Lived Assets | (g) Impairment of Long-Lived Assets |
Financial Instruments and Fair Value Measurements | (h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. |
Related Party Transactions | (i) Related Party Transactions |
Revenue Recognition | (j) Revenue Recognition |
Stock based compensation | (k) Stock based compensation |
Income Taxes | (l) Income Taxes |
Net income (loss) per share | (m) Net income (loss) per share no . |
Recent Accounting Pronouncements | (n) Recent Accounting Pronouncements |
DEFICIENCY IN STOCKHOLDERS EQ_2
DEFICIENCY IN STOCKHOLDERS EQUITY (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
SCHEDULE OF STOCKHOLDERS EQUITY | SCHEDULE OF STOCKHOLDERS EQUITY No. Shares Par No. Shares Par No. Shares Par No. Shares Par Series A Series B Series C Total No. Shares Par No. Shares Par No. Shares Par No. Shares Par January 1, 2020 34,109,750 $ 3,411 293,000 $ 29 - $ - 34,402,750 $ 3,440 Issuance of shares for services 100,000,000 10,000 - - 30,000,000 3,000 130,000,000 13,000 December 31, 2020 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Beginning Balance 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Conversion to common shares (134,109,750 ) (13,411 ) (212,000 ) (21 ) - - (134,321,750 ) (13,432 ) December 31, 2021 - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 Ending Balance - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 |
GENERAL AND ADMINISTRATIVE EX_2
GENERAL AND ADMINISTRATIVE EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
General And Administrative Expenses | |
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE | SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE 2021 2020 Year ended December 31, 2021 2020 Salaries $ 1,016,881 $ 143,065 Share based compensation 2,889,567 4,302,978 Professional fees 225,384 117,860 Other 79,523 34,399 Total general and administrative expenses $ 4,211,355 $ 4,598,302 Curative Biotechnology, Inc Notes to Financial Statements |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE | The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2021 2020 Current $ - $ - Deferred $ - $ - Total tax provisions $ - $ - |
SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE | The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE 2021 2020 U.S. Federal statutory income tax rate (21 )% (21 )% State income tax, net of federal benefit (4.5 )% (4.5 )% Valuation allowance 25.5 % 25.5 % Total 0.0 % 0.0 % |
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES | The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Deferred tax assets: Net operating loss carry forwards $ 1,337,957 $ 831,988 Stock based compensation 1,600,548 958,197 Other - (10,061 ) Total 2,938,505 1,780,124 Deferred tax liabilities: - - Less: valuation allowance (2,938,505 ) (1,780,124 ) Net deferred tax assets $ - $ - |
SIGNIFICANT ACCOUNTING POLICI_3
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||
Dilutive shares of common stock equivalents | 0 | 0 |
LIQUIDITY AND GOING CONCERN C_2
LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Net loss | $ 5,340,354 | $ 4,670,255 |
Accumulated deficit | $ 26,917,036 | $ 8,099,627 |
INTANGIBLE ASSETS (Details Narr
INTANGIBLE ASSETS (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2021 | Jan. 31, 2021 | Dec. 31, 2020 | Oct. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license | $ 1,425,000 | $ 106,000 | |||||||||
Common stock issued for services, value | $ 21,960 | $ 325,000 | $ 23,300 | $ 15,000 | 540,136 | 36,800 | |||||
Common stock issued for services, shares | 200,000 | 6,500,000 | 1,250,000 | 1,500,000 | |||||||
Payment for royalty free perpetual license | 14,500 | $ 34,300 | |||||||||
Website [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued for services, value | $ 22,500 | $ 15,000 | |||||||||
Amortization period | 3 years | ||||||||||
Amortization expense | $ 6,250 | ||||||||||
Common stock issued for services, shares | 1,500,000 | ||||||||||
Patents [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
License transaction description | The total cost for this license is 20 million shares of the Company’s common stock, issuable in three tranches - 1- 7 million shares upon execution of the license (which have been issued, valued at $91,000), 2- 6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504. | ||||||||||
Patents [Member] | Investigational New Drug [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 20,000,000 | ||||||||||
Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 91,000 | ||||||||||
Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Minimum [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 1,000,000 | ||||||||||
Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Maximum [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 7,000,000 | ||||||||||
Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Minimum [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 2,000,000 | ||||||||||
Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Maximum [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 6,500,000 | ||||||||||
Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Minimum [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 3,000,000 | ||||||||||
Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Maximum [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 6,500,000 | ||||||||||
National Institute of Health Patent License One [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Payment of non-refundable license issue royalty | $ 10,000 | ||||||||||
National Institute of Health Patent License Two [Member] | Royalty [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Patent expense initial amount payable | $ 8,500 | ||||||||||
National Institute of Health Patent License Two [Member] | Royalty One [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
License extension terms | The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty | ||||||||||
Payment of non-refundable license issue royalty | $ 45,000 | ||||||||||
Patent expense initial amount payable | $ 5,000 | ||||||||||
Mid-Atlantic BioTheraputics, Inc [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Common stock issued to acquire license, shares | 12,500,000 | ||||||||||
Common stock issued to acquire license | $ 1,425,000 | ||||||||||
Mid-Atlantic BioTheraputics, Inc [Member] | Patents [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Proceeds for patent license development | 6,500,000 | ||||||||||
IEM, Inc [Member] | Patents [Member] | |||||||||||
Finite-Lived Intangible Assets [Line Items] | |||||||||||
Cost of option | $ 1,800 | ||||||||||
License extension terms | The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $50,000 in exchange for an exclusive world-wide, royalty free perpetual license. In September 2021, the Company exercised the option to extend the deadline for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of $1,000 | ||||||||||
Payment for royalty free perpetual license | $ 50,000 | ||||||||||
Payment for extension | $ 1,000 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2021 | |
Related Party Transaction [Line Items] | |||
Advances from related party | $ 48,083 | ||
Officer [Member] | Two Notes [Member] | |||
Related Party Transaction [Line Items] | |||
Payment of principal amount | $ 40,000 | ||
Original issue discount | $ 10,000 |
NOTES PAYABLE (Details Narrativ
NOTES PAYABLE (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |||
Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2021 | Jun. 30, 2021 | |
Short-Term Debt [Line Items] | |||||
Cash received | $ 70,000 | ||||
Purchase of common stock warrants | 25,915,437 | 4,236,111 | 5,000,000 | ||
Share Price | $ 0.114 | ||||
Thirteen Notes [Member] | |||||
Short-Term Debt [Line Items] | |||||
Debt notes converted into shares of common stock | 10,937,499 | ||||
Two Notes Payable [Member] | |||||
Short-Term Debt [Line Items] | |||||
Debt face amount | $ 137,500 | $ 568,750 | |||
Original issue discount, percentage | 25.00% | ||||
Cash received | $ 110,000 | ||||
Maturity term | 6 months | ||||
Maturity extension description | The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee | ||||
Purchase of common stock warrants | 1,100,000 | 4,550,000 | |||
Debt discount amount | $ 9,533 | ||||
Two Notes Payable [Member] | Series C Preferred Stock [Member] | |||||
Short-Term Debt [Line Items] | |||||
Issued and outstanding common stock shares, percentage | 9.24% | ||||
Thirteen Notes Payable [Member] | |||||
Short-Term Debt [Line Items] | |||||
Debt notes converted into shares of common stock | 10,937,499 | ||||
Original issue discount, percentage | 25.00% | ||||
Cash received | $ 455,000 | ||||
Maturity term | 6 months | ||||
Maturity extension description | The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee | ||||
Debt discount amount | $ 54,555 | ||||
Share Price | $ 0.06 | ||||
Debt Conversion, Converted Instrument, Amount | $ 656,250 | ||||
Thirteen Notes Payable [Member] | Series C Preferred Stock [Member] | |||||
Short-Term Debt [Line Items] | |||||
Issued and outstanding common stock shares, percentage | 9.24% |
CONVERTIBLE NOTE PAYABLE (Detai
CONVERTIBLE NOTE PAYABLE (Details Narrative) - USD ($) | Apr. 30, 2013 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 |
Short-Term Debt [Line Items] | |||||||
Issuance of common stock, shares | 13,159,331 | 4,361,111 | 10,000,000 | 8,500,000 | |||
Convertible Notes Payable [Member] | |||||||
Short-Term Debt [Line Items] | |||||||
Debt instrument face amount | $ 97,500 | ||||||
Debt instrument interest rate | 4.00% | ||||||
Debt conversion price percentage | 90.00% | ||||||
Debt instrument conversion price per share | $ 0.001 | ||||||
Accrued interest | $ 128,700 | ||||||
Debt payment amount | $ 100,000 | ||||||
Issuance of common stock, shares | 2,000,000 |
LIABILITY TO ISSUE COMMON STO_2
LIABILITY TO ISSUE COMMON STOCK (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
Mar. 31, 2020 | Dec. 31, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Issuance of common stock for services, shares | 200,000 | 6,500,000 | 1,250,000 | 1,500,000 | |||
Issuance of common stock for services, value | $ 21,960 | $ 325,000 | $ 23,300 | $ 15,000 | $ 540,136 | $ 36,800 | |
Common Stock [Member] | |||||||
Issuance of common stock for services, shares | 1,000,000 | 125,000 | 8,715,000 | 1,700,000 | |||
Issuance of common stock for services, value | $ 7,400 | $ 5,575 | $ 872 | $ 170 |
SCHEDULE OF STOCKHOLDERS EQUITY
SCHEDULE OF STOCKHOLDERS EQUITY (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Balance | $ (4,521,640) | $ (88,435) | $ (4,521,640) | $ (88,435) | ||||
Common shares issued for services | $ 21,960 | $ 325,000 | $ 23,300 | $ 15,000 | 540,136 | 36,800 | ||
Common shares issued for services, shares | 200,000 | 6,500,000 | 1,250,000 | 1,500,000 | ||||
Conversion to common shares | 1,564,251 | |||||||
Balance | $ (16,361,742) | $ (4,521,640) | (16,361,742) | (4,521,640) | ||||
Series A Preferred Stock [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common shares issued for services | $ 1,560,840 | |||||||
Common shares issued for services, shares | 100,000,000 | |||||||
Preferred Stock [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Balance | $ 29 | $ 29 | $ 29 | $ 29 | ||||
Balance, shares | 164,402,750 | 34,402,750 | 164,402,750 | 34,402,750 | ||||
Common shares issued for services | ||||||||
Conversion to common shares | [1] | |||||||
Conversion to common shares, shares | (134,109,750) | |||||||
Balance | $ 8 | $ 29 | $ 8 | $ 29 | ||||
Balance, shares | 30,081,000 | 164,402,750 | 30,081,000 | 164,402,750 | ||||
Preferred Stock [Member] | Series A Preferred Stock [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Balance | $ 13,411 | $ 3,411 | $ 13,411 | $ 3,411 | ||||
Balance, shares | 134,109,750 | 34,109,750 | 134,109,750 | 34,109,750 | ||||
Common shares issued for services | $ 10,000 | |||||||
Common shares issued for services, shares | 100,000,000 | |||||||
Conversion to common shares | $ (13,411) | |||||||
Conversion to common shares, shares | (134,109,750) | |||||||
Balance | $ 13,411 | $ 13,411 | ||||||
Balance, shares | 134,109,750 | 134,109,750 | ||||||
Preferred Stock [Member] | Series B Preferred Stock [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Balance | $ 29 | $ 29 | $ 29 | $ 29 | ||||
Balance, shares | 293,000 | 293,000 | 293,000 | 293,000 | ||||
Common shares issued for services | ||||||||
Common shares issued for services, shares | ||||||||
Conversion to common shares | $ (21) | |||||||
Conversion to common shares, shares | (212,000) | |||||||
Balance | $ 8 | $ 29 | $ 8 | $ 29 | ||||
Balance, shares | 81,000 | 293,000 | 81,000 | 293,000 | ||||
Preferred Stock [Member] | Series C Preferred Stock [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Balance | $ 3,000 | $ 3,000 | ||||||
Balance, shares | 30,000,000 | 30,000,000 | ||||||
Common shares issued for services | $ 3,000 | |||||||
Common shares issued for services, shares | 30,000,000 | |||||||
Conversion to common shares | ||||||||
Conversion to common shares, shares | ||||||||
Balance | $ 3,000 | $ 3,000 | $ 3,000 | $ 3,000 | ||||
Balance, shares | 30,000,000 | 30,000,000 | 30,000,000 | 30,000,000 | ||||
Preferred Stock [Member] | Series A, B and C Preferred Stock [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Balance | $ 16,440 | $ 3,440 | $ 16,440 | $ 3,440 | ||||
Balance, shares | 164,402,750 | 34,402,750 | 164,402,750 | 34,402,750 | ||||
Common shares issued for services | $ 13,000 | |||||||
Common shares issued for services, shares | 130,000,000 | |||||||
Conversion to common shares | $ (13,432) | |||||||
Conversion to common shares, shares | (134,321,750) | |||||||
Balance | $ 3,008 | $ 16,440 | $ 3,008 | $ 16,440 | ||||
Balance, shares | 30,081,000 | 164,402,750 | 30,081,000 | 164,402,750 | ||||
[1] | Series A and Series C Preferred Stock amounts reflected in mezzanine equity |
DEFICIENCY IN STOCKHOLDERS EQ_3
DEFICIENCY IN STOCKHOLDERS EQUITY (Details Narrative) - USD ($) | Jan. 20, 2022 | Apr. 30, 2013 | Aug. 31, 2022 | May 31, 2022 | Apr. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Aug. 31, 2021 | May 31, 2021 | Mar. 31, 2020 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Jan. 31, 2022 |
Class of Stock [Line Items] | ||||||||||||||||||||||
Common stock, shares authorized | 1,100,000,000 | 1,100,000,000 | 1,100,000,000 | 1,100,000,000 | 1,100,000,000 | |||||||||||||||||
Common stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||
Common stock, shares issued | 570,651,636 | 570,651,636 | 333,000,327 | 570,651,636 | 333,000,327 | |||||||||||||||||
Common stock, shares outstanding | 570,651,636 | 570,651,636 | 333,000,327 | 570,651,636 | 333,000,327 | |||||||||||||||||
Preferred stock, shares authorized | 200,000,000 | 200,000,000 | 200,000,000 | 200,000,000 | 200,000,000 | |||||||||||||||||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||
Shares issued | 13,159,331 | 4,361,111 | 10,000,000 | 8,500,000 | ||||||||||||||||||
Warrants to purchase of common stock | 25,915,437 | 4,236,111 | 25,915,437 | 4,236,111 | 5,000,000 | 4,236,111 | 25,915,437 | |||||||||||||||
Common stock value | $ 600,000 | $ 106,000 | $ 1,573,000 | |||||||||||||||||||
Security deposit | $ 25,000 | $ 25,000 | 25,000 | |||||||||||||||||||
Common shares issued for services, shares | 200,000 | 6,500,000 | 1,250,000 | 1,500,000 | ||||||||||||||||||
Common shares issued for services | $ 21,960 | $ 325,000 | $ 23,300 | $ 15,000 | $ 540,136 | $ 36,800 | ||||||||||||||||
Shares vested | 60,000 | 250,000 | 60,000 | 250,000 | 60,000 | 60,000 | ||||||||||||||||
Warrant maturity date | 2024-12 | 2026-07 | 2026-05 | |||||||||||||||||||
Warrant exercise price | $ 0.11 | $ 0.11 | $ 0.11 | $ 0.11 | ||||||||||||||||||
Number of common stock to settle the liability to issue shares | 1,000,000 | |||||||||||||||||||||
Shares issued price per share | $ 0.01 | $ 0.06 | $ 0.0216 | $ 0.01864 | $ 0.01 | $ 0.0216 | ||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 1,564,251 | |||||||||||||||||||||
Exercise of warrants for services shares | 6,500,000 | |||||||||||||||||||||
Exchange of shares for services, shares | 1,700,000 | |||||||||||||||||||||
Exchange of shares for services, valued | $ 36,800 | 7,400 | ||||||||||||||||||||
Vesting rate description | 50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which will be amortized over the remaining of the six month service period. | |||||||||||||||||||||
Deemed dividend | $ 13,477,055 | $ 4,440 | ||||||||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Conversion price percentage | 90.00% | |||||||||||||||||||||
Shares issued | 2,000,000 | |||||||||||||||||||||
Debt instrument convertible conversion price | $ 0.001 | |||||||||||||||||||||
Common shares issued for services, shares | 2,000,000 | |||||||||||||||||||||
Common shares issued for services | $ 180,000 | |||||||||||||||||||||
Forecast [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Shares vested | 70,000 | 70,000 | ||||||||||||||||||||
Subsequent Event [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Common stock, shares authorized | 1,000,000 | |||||||||||||||||||||
Shares vested | 250,000 | 250,000 | 60,000 | |||||||||||||||||||
Advisory Board [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Common shares issued for services, shares | 250,000 | 250,000 | ||||||||||||||||||||
Common shares issued for services | $ 22,500 | |||||||||||||||||||||
Board of Directors [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Common shares issued for services, shares | 300,000 | |||||||||||||||||||||
Common shares issued for services | $ 36,720 | |||||||||||||||||||||
Advisory Board One [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Common shares issued for services, shares | 250,000 | |||||||||||||||||||||
Common shares issued for services | $ 28,475 | |||||||||||||||||||||
Employee [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Common shares issued for services, shares | 840,000 | |||||||||||||||||||||
Shares vested | 210,000 | 210,000 | ||||||||||||||||||||
Employee [Member] | Subsequent Event [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Shares vested | 210,000 | |||||||||||||||||||||
Employees [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Shares vested | 210,000 | |||||||||||||||||||||
Two Employees [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Common shares issued for services, shares | 840,000 | |||||||||||||||||||||
MABT's COVID-19 Vaccine [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Shares issued | 12,500,000 | |||||||||||||||||||||
Common stock value | $ 1,425,000 | |||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Shares issued | 10,500,000 | 27,520,442 | ||||||||||||||||||||
Warrants to purchase of common stock | 403,225 | 4,236,111 | 403,225 | 4,236,111 | 10,500,000 | 4,550,000 | 4,236,111 | 403,225 | 4,550,000 | |||||||||||||
Common stock value | $ 523,000 | $ 425,000 | $ 525,000 | $ 2,752 | ||||||||||||||||||
Common shares issued for services, shares | 1,000,000 | 125,000 | 8,715,000 | 1,700,000 | ||||||||||||||||||
Common shares issued for services | $ 7,400 | $ 5,575 | $ 872 | $ 170 | ||||||||||||||||||
Warrant exercise price | $ 0.05 | $ 0.05 | ||||||||||||||||||||
Shares issued price per share | $ 0.0446 | $ 0.0125 | 0.0125 | |||||||||||||||||||
Number of common stock to settle a payable | 375,000 | |||||||||||||||||||||
Value of common stock to settle a payable | $ 11,250 | |||||||||||||||||||||
Shares issued | 10,937,499 | 135,836,702 | ||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 656,250 | $ 13,584 | ||||||||||||||||||||
Exchange of shares for services, shares | 1,000,000 | |||||||||||||||||||||
Exchange of shares for services, valued | $ 100 | |||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Preferred stock, voting rights | Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date | |||||||||||||||||||||
Conversion price percentage | 35.00% | |||||||||||||||||||||
Redeemable price percentage | 45.00% | |||||||||||||||||||||
Shares issued | 5,000,000 | |||||||||||||||||||||
Common shares issued for services, shares | 100,000,000 | |||||||||||||||||||||
Common shares issued for services | $ 1,560,840 | |||||||||||||||||||||
Perferred stock converted into common stock | 135,836,702 | |||||||||||||||||||||
Shares issued price per share | $ 0.0156 | 0.0156 | ||||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Redeemable price percentage | 125.00% | |||||||||||||||||||||
Debt instrument convertible conversion price | $ 0.0075 | $ 0.0075 | $ 0.0075 | |||||||||||||||||||
Number of preferred stock converted | 9,000 | 9,000 | 203,000 | 9,000 | ||||||||||||||||||
Perferred stock converted into common stock | 1,200,000 | 1,200,000 | 27,066,666 | 1,200,000 | ||||||||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||
Conversion price percentage | 30.00% | |||||||||||||||||||||
Shares issued price per share | $ 0.152 | $ 0.152 | ||||||||||||||||||||
Exchange of shares for services, shares | 30,000,000 | |||||||||||||||||||||
Exchange of shares for services, valued | $ 4,562,062 |
WARRANTS (Details Narrative)
WARRANTS (Details Narrative) - USD ($) | Jan. 20, 2022 | May 31, 2022 | Apr. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Aug. 31, 2021 | May 31, 2021 | Mar. 31, 2020 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 |
Warrants to purchase | 25,915,437 | 4,236,111 | 25,915,437 | 4,236,111 | 5,000,000 | 25,915,437 | |||||||||||
Sale of common stock | 403,225 | 4,361,111 | 10,000,000 | ||||||||||||||
Warrant term | 2024-12 | 2026-07 | 2026-05 | ||||||||||||||
Warrant exercise price per share | $ 0.11 | $ 0.11 | $ 0.11 | $ 0.11 | |||||||||||||
Warrants outstanding | $ 87,249 | ||||||||||||||||
Shares vested | 60,000 | 250,000 | 60,000 | 250,000 | 60,000 | 60,000 | |||||||||||
Stock Issued During Period, Value, New Issues | $ 600,000 | $ 106,000 | $ 1,573,000 | ||||||||||||||
Exercise of warrants shares | 10,500,000 | ||||||||||||||||
SharesIssued | 6,500,000 | ||||||||||||||||
Common shares issued for services | $ 21,960 | $ 325,000 | $ 23,300 | $ 15,000 | $ 540,136 | $ 36,800 | |||||||||||
Common shares issued for services, shares | 200,000 | 6,500,000 | 1,250,000 | 1,500,000 | |||||||||||||
Expected term | 10 years | 5 years | 3 years | ||||||||||||||
Share price | $ 0.114 | $ 0.114 | |||||||||||||||
Expected volatility rate | 35.13% | ||||||||||||||||
Exercise price | 0.11 | $ 0.11 | |||||||||||||||
Expected dividend rate | 1.47% | ||||||||||||||||
Two Peoples [Member] | |||||||||||||||||
Warrants to purchase | 6,750,000 | 6,750,000 | |||||||||||||||
Warrant outstanding amount | $ 44,135 | $ 44,135 | |||||||||||||||
Share price | $ 0.03 | $ 0.03 | |||||||||||||||
Exercise price | $ 0.05 | $ 0.05 | |||||||||||||||
Subsequent Event [Member] | |||||||||||||||||
Shares vested | 250,000 | 250,000 | 60,000 | ||||||||||||||
Legal Services [Member] | |||||||||||||||||
Warrants to purchase | 3,000,000 | ||||||||||||||||
Warrant outstanding amount | $ 155,717 | ||||||||||||||||
Minimum [Member] | |||||||||||||||||
Warrant exercise price per share | $ 0.09 | 0.15 | $ 0.09 | $ 0.15 | $ 0.20 | $ 0.09 | |||||||||||
Minimum [Member] | Two Peoples [Member] | |||||||||||||||||
Expected volatility rate | 30.22% | ||||||||||||||||
Expected dividend rate | 0.08% | ||||||||||||||||
Maximum [Member] | |||||||||||||||||
Warrant exercise price per share | $ 0.15 | $ 0.14 | $ 0.15 | $ 0.14 | 0.10 | $ 0.05 | $ 0.15 | ||||||||||
Maximum [Member] | Two Peoples [Member] | |||||||||||||||||
Expected volatility rate | 109.96% | ||||||||||||||||
Expected dividend rate | 0.11% | ||||||||||||||||
Maximum [Member] | Legal Services [Member] | |||||||||||||||||
Warrant exercise price per share | $ 0.10 | ||||||||||||||||
Common Stock [Member] | |||||||||||||||||
Warrants to purchase | 403,225 | 4,236,111 | 403,225 | 4,236,111 | 10,500,000 | 4,550,000 | 403,225 | 4,550,000 | |||||||||
Warrant exercise price per share | $ 0.05 | $ 0.05 | |||||||||||||||
Warrant outstanding amount | $ 54,555 | $ 54,555 | |||||||||||||||
Stock Issued During Period, Value, New Issues | $ 523,000 | $ 425,000 | $ 525,000 | $ 2,752 | |||||||||||||
Common shares issued for services | $ 7,400 | $ 5,575 | $ 872 | $ 170 | |||||||||||||
Common shares issued for services, shares | 1,000,000 | 125,000 | 8,715,000 | 1,700,000 | |||||||||||||
Warrants, description | the Company in conjunction with the short term debt at the rate of 10 warrants for each $1 loaned. | the Company in conjunction with the issuance of short term debt at the rate of 10 warrants for each $1 loaned | |||||||||||||||
Warrant [Member] | |||||||||||||||||
Warrants to purchase | 25,512,212 | 1,000,000 | 25,512,212 | 1,000,000 | 1,000,000 | 1,100,000 | 25,512,212 | ||||||||||
Sale of common stock | 12,756,106 | ||||||||||||||||
Warrant term | 2024-12 | 2024-07 | |||||||||||||||
Warrant exercise price per share | $ 0.124 | $ 0.124 | $ 0.05 | $ 0.05 | |||||||||||||
Warrant outstanding amount | $ 34,382 | $ 34,382 | $ 51,906 | $ 9,533 | |||||||||||||
Common shares issued for services | $ 325,000 | ||||||||||||||||
Warrants [Member] | |||||||||||||||||
Warrants to purchase | 5,000,000 | ||||||||||||||||
Warrant exercise price per share | $ 0.05 | ||||||||||||||||
Warrant outstanding amount | $ 40,600 | ||||||||||||||||
Warrants [Member] | Minimum [Member] | |||||||||||||||||
Share price | $ 0.04 | ||||||||||||||||
Expected volatility rate | 60.51% | ||||||||||||||||
Exercise price | $ 0.05 | ||||||||||||||||
Expected dividend rate | 0.09% | ||||||||||||||||
Warrants [Member] | Maximum [Member] | |||||||||||||||||
Share price | $ 0.10 | ||||||||||||||||
Expected volatility rate | 31.56% | ||||||||||||||||
Exercise price | $ 0.2 | ||||||||||||||||
Expected dividend rate | 0.83% |
OPTIONS (Details Narrative)
OPTIONS (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
Sep. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||
Shares issued for cash, shares | 13,159,331 | 4,361,111 | 10,000,000 | 8,500,000 | |||
Share price | $ 0.114 | ||||||
Shares issued for cash | $ 600,000 | $ 106,000 | $ 1,573,000 | ||||
Expected term | 10 years | 5 years | 3 years | ||||
Volatility rate | 35.13% | ||||||
Exercise price | $ 0.11 | ||||||
Expected dividend rate | 1.47% | ||||||
Board of Advisory [Member] | |||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||
[custom:OptionsPercentage] | 1.00% | ||||||
Shares issued for cash, shares | 8,081,037 | ||||||
Proceeds from offering | $ 5 | ||||||
Share price | $ 0.11 | ||||||
Shares issued for cash | $ 436,908 | ||||||
Options vested percentage | 50.00% | ||||||
Board of Advisory [Member] | Subsequent Event [Member] | |||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |||||||
Options vested percentage | 50.00% |
SCHEDULE OF GENERAL AND ADMINIS
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
General And Administrative Expenses | ||
Salaries | $ 1,016,881 | $ 143,065 |
Share based compensation | 2,889,567 | 4,302,978 |
Professional fees | 225,384 | 117,860 |
Other | 79,523 | 34,399 |
Total general and administrative expenses | $ 4,211,355 | $ 4,598,302 |
IMPAIRMENT OF LONG LIVED ASSE_2
IMPAIRMENT OF LONG LIVED ASSETS (Details Narrative) - USD ($) | 3 Months Ended | ||
Dec. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |||
Depreciation | $ 1,958 | ||
Indefinite lved intangble assets written off | $ 15,000 | ||
Impairment charge | $ 34,516 |
SCHEDULE OF COMPONENTS OF INCOM
SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Current | ||
Deferred | ||
Total tax provisions |
SCHEDULE OF EFFECTIVE RECONCILI
SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
U.S. Federal statutory income tax rate | (21.00%) | (21.00%) |
State income tax, net of federal benefit | (4.50%) | (4.50%) |
Valuation allowance | 25.50% | 25.50% |
Total | 0.00% | 0.00% |
SCHEDULE OF DEFERRED TAX ASSETS
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Income Tax Disclosure [Abstract] | ||
Net operating loss carry forwards | $ 1,337,957 | $ 831,988 |
Stock based compensation | 1,600,548 | 958,197 |
Other | (10,061) | |
Total | 2,938,505 | 1,780,124 |
Less: valuation allowance | (2,938,505) | (1,780,124) |
Net deferred tax assets |
INCOME TAXES (Details Narrative
INCOME TAXES (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Deferred tax asset change in valuation allowance | $ 1,158,381 | $ 1,021,331 |
Effective income tax rate percentage | 100.00% |
CONCENTRATIONS OF CREDIT RISK (
CONCENTRATIONS OF CREDIT RISK (Details Narrative) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Risks and Uncertainties [Abstract] | ||
Cash, FDIC insured amount | $ 416,178 | $ 0 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | 1 Months Ended | ||||||
Sep. 30, 2022 | Mar. 31, 2022 | Jan. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | |
Subsequent Event [Line Items] | |||||||
Purchase of common stock warrants | 25,915,437 | 4,236,111 | 5,000,000 | ||||
Exercise price | $ 0.11 | $ 0.11 | |||||
Common stock shares | 1,100,000,000 | 1,100,000,000 | |||||
Common stock | $ 57,065 | $ 33,300 | |||||
Common Stock, Shares, Issued | 570,651,636 | 333,000,327 | |||||
Share price | $ 0.114 | ||||||
Subsequent Event [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Payment of principal amount | $ 179,592 | ||||||
Common stock shares | 1,000,000 | ||||||
Common stock | $ 51,750 | ||||||
Common stock value subscriptions | $ 25,000 | ||||||
Subsequent Event [Member] | Equity Option [Member] | Three Employees [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Common Stock, Shares, Issued | 7,465,500 | ||||||
Option term | 5 years | ||||||
Share price | $ 0.05175 | ||||||
Payments to purchase common stock | $ 155,250 | ||||||
Subsequent Event [Member] | Senior Notes [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Payment of principal amount | $ 1,142,857 | ||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.50% | ||||||
Debt instrument, payment terms | The Note carries a 12.5% interest rate with interest only payable monthly from April through August 2022. | ||||||
Debt instrument, interest rate, percentage | 12.50% | ||||||
Proceeds from debt | $ 874,286 | ||||||
Debt discount | $ 1,000,000 | 142,857 | |||||
Legal fees | $ 125,714 | ||||||
Monthly redemptions | 110.00% | ||||||
Mandatory prepayment of original principal amount, percentage | 125.00% | ||||||
Debt instrument, long term debt | $ 1,428,571 | ||||||
Purchase of common stock warrants | 22,857,143 | ||||||
Exercise price | $ 0.0001 |